INP20, a peanut oral immunotherapy, is well tolerated by peanut-allergic patients in a double-blind placebo-controlled phase I clinical trial

INP20 is an oral nanoparticle-based peanut immunotherapy that is being tested in a double-blind placebo-controlled phase I clinical trial. The goal of this project is to evaluate the safety of this treatment in peanut-allergic patients.

Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Marta Ferrer, Maria Jose Zavala, Jimena Crespo, Carmen D, Evelyn Gutierrez, Blanca Esther Garc ía, Gabriel Gastaminza, Sara Gomez, Natalia Martinez de Baroja, Jorge Morales, Maite Agüeros, Ana Isabel Tabar Purroy Source Type: research